Clinical Trials Logo

HER2-Positive Solid Tumors clinical trials

View clinical trials related to HER2-Positive Solid Tumors.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04501770 Not yet recruiting - Clinical trials for HER2-Positive Solid Tumors

A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors

Start date: August 28, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of different doses of M802 in patients with HER2-positive advanced solid tumors, and to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) so as to provide basis for the recommended phase 2 dose (RP2D).